Trial · NCT05178043
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
NCT05178043, Phase 2, Unknown, Suzhou Kintor Pharmaceutical Inc,
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma. Trials, record NCT05178043. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05178043
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
- NCT number
- NCT05178043
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Conditions
- Hepatocellular Carcinoma, HCC
- Interventions
- Nivolumab, GT90001
- First posted
- 2022-01-05
- Last updated
- 2024-02-22
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Objective Response Rate (ORR) (confirmed) as evaluated by an Independent Review Committee (IRC) according to RECIST v1.1 | Approximately 2 years | ORR is defined as the proportion of participants with best overall response of confirmed complete response (CR) or partial response (PR). RECIST: Response Evaluation Criteria in Solid Tumors |
| Secondary | Duration OF Response (DOR) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | Progression Free Survival (PFS) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | Time To Response (TTR) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | Time to Progression (TTP) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | Disease Control Rate (DCR) as evaluated by an IRC according to RECIST v1.1 | Approximately 2 years | |
| Secondary | ORR (confirmed) as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years | |
| Secondary | DOR as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years | |
| Secondary | PFS as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years | |
| Secondary | TTR as evaluated by the investigator according to RECIST v1.1 | Approximately 2 years |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05178043
GET https://conductscience.org/api/trials/v1/NCT05178043/registered?page=2